

✓ HPLC + MS third-party tested
✓ Ships from the USA in 1–3 business days
✓ Public COA — no request needed

Sealed and capped — one compound per vial
GLP-3 RT
For research use onlySKU RT20 · Purity 99.6%
Size
Kit & Save
- ✓Free US shipping on orders $100+ · ships in 1–3 business days
- ✓Free Shipment Protection — lost or damaged in transit, we replace it, no return needed
- ✓Free Bacteriostatic Water on orders $50+
- ✓30-day replacement guarantee on unopened vials
- ✓Tested by Janoshik Analytical — HPLC + Mass Spectrometry
Researchers also added
Certificate of Analysis (COA)
Every batch is independently tested by a third-party US lab for HPLC purity and mass-spec identity.
View third-party COA for GLP-3 RTRetatrutide (LY-3437943) reference material — a synthetic peptide investigated in published academic literature as a multi-receptor agonist (MW ~4813 Da). Synthesized at >98% purity with identity confirmed by LC-MS/MS. Supplied as lyophilized powder requiring cold-chain storage at -20°C; cold-pack shipping recommended. Reconstitute with bacteriostatic water. For in-vitro laboratory and analytical research use only. Not a drug, supplement, or therapeutic product. Not for human or animal consumption, ingestion, injection, or any clinical use. Not FDA-approved or evaluated for safety or efficacy.
Also known as: Retatrutide, LY3437943
For laboratory research use only. Not for human or animal consumption.
A new standard for peptide manufacturing
For research use only
Step 01
Sourcing
Vetted manufacturing partners under documented synthesis controls — not anonymous overseas resellers repacking unknown stock.
Research dossier
OverviewRetatrutide (LY3437943) is a novel triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 clinical trial data published in the New England Journal of Medicine (2023;389:514-526) reported significant metabolic effects. Research in Diabetes Care (2023;46(5):e124-e125) explored its pharmacokinetic profile. Preclinical studies published in Cell Metabolism (2022;34(12):1823-1835) demonstrated multi-receptor binding properties and downstream signaling cascades in cell-based assays.
For laboratory research use only. Not for human, veterinary, or diagnostic use.
Frequently Asked Questions
For Research Use OnlyQuality, verified three ways
Chromatographic purity is reported as HPLC area percent, and identity is confirmed by mass spectrometry matching the expected molecular weight. Every result is published as a third-party tested COA.
Sources & References
Peer-reviewed research
New England Journal of Medicine
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
2023 · DOI: 10.1056/NEJMoa2301972
Jastreboff AM, et al.
The Lancet
Retatrutide for People with Type 2 Diabetes — A Phase 2 Trial
2023
Rosenstock J, et al.
Nature Medicine
Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease
2024
Sanyal AJ, et al.
Lancet Diabetes & Endocrinology
Effects of Retatrutide on Body Composition
2025
Coskun T, et al.
Related research reading
Background articles from our research library for GLP-3 RT. For laboratory research context only.
- Which research peptides are actually being studied in 2026?
- The complete timeline of peptide research: 1921 to 2026
- Peptide storage stress test: what happens if you don't refrigerate
- State of Purity 2026: we tested 15 BPC-157 suppliers
- How to reconstitute peptides: step-by-step guide
- We fact-checked 10 peptide research claims from Reddit
RESEARCH CHEMICALS ONLY
This product is intended for laboratory research use only. Not for human consumption, therapeutic, or diagnostic purposes. Not an FDA-approved drug.
Be the first to review this product
Purchased and used it in your research? Share what you observed — your feedback helps other researchers evaluate this batch.
Continue browsing






